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Background: While self-reported data are commonly used as a source of medication use for 
pharmaco-epidemiological studies, such information is prone to forms of bias. Several previ-
ous studies showed that various factors like age, type of drug and data collection method may 
influence accuracy. We aimed to assess the concordance of the self-reported medication use that 
was documented at entry to the Lifelines Cohort Study, a three-generation follow-up study in 
the Netherlands that started in 2006 and included over 167,000 participants. 
Materials and methods: As part of the PharmLines Initiative, we collected medication data 
from the Lifelines participants encoded according to the Anatomical Therapeutic Chemical 
(ATC) coding scheme and linked the data via Statistics Netherlands to the widely used and rep-
resentative pharmacy prescription database of the University of Groningen, IADB.nl. Analyses 
were conducted at second level of ATC coding for all recorded medications as well as a top 
list of most used medications at drug-specific fifth level. Cohen’s kappa statistics were used to 
measure the concordance for all participants according to sex and age.
Results: The level of concordance between the two data sources largely differed according to the 
therapeutic class. Medication used for the cardiovascular system and diabetes, thyroid therapy, 
bisphosphonates and anti-thrombotic drugs showed a very good agreement (κ>0.75). Medication 
as needed or prone to stigmatization bias showed a moderate agreement (κ=0.41–0.60), whereas 
medications used for short periods of time showed a fair agreement (κ=0.0–0.4). Concordance 
was similar for males and females, but younger adults tended to have lower concordance rates 
than older adults. 
Conclusion: The self-reported method was valid for capturing prevalent chronic medication 
use at one moment in time, but invalid for medication used for short periods of time. There is 
no effect of sex on the agreement, and more studies are needed on the influence of age. Future 
pharmaco-epidemiological studies should preferably combine the two data sources to achieve 
the highest accuracy of drug exposure rates. 
Keywords: self-reported data, prescription data, pharmacy records, agreement, questionnaire, 
medication, interview, validity
Introduction
The Lifelines Cohort Study was started in 2006 to study risk factors for disease 
development in the long-term and to conduct “real-world” pharmaco-epidemiological 
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studies using self-reported data to determine exposure to 
medications.1,2 However, self-reported data are prone to 
recall bias, which can result in substantial (non-)differential 
misclassification of actual drug exposure and hence may 
lead to an underestimation or overestimation of the true 
medication use and effects.3–5 Due to their high accuracy, 
electronic medication records (EMR) are usually seen as 
the golden standard compared to self-reported medication 
use.6 By contrast, self-reported data contain information on 
which medication is actually used by the respondent and may 
also provide information about usage of over-the-counter 
(OTC) medication and herbal medicines.7 To date, few stud-
ies evaluated the concordance of self-reported medication 
use compared to EMR, and the results are inconsistent.8–15 
These studies reported good agreement between self-reported 
medication use and electronic records in most instances, 
but agreement varied significantly by therapeutic group. 
For example, in some studies a remarkably high agreement 
between pharmacy records and self-reports was shown for 
medication used chronically such as cardiovascular drugs, 
drugs for diabetes, anticoagulation-related drugs and hor-
monal drug treatments.8–11 By contrast, lower concordance 
rates were observed for medication taken topically, as needed 
or for shorter periods.7,12,13 Studies in various settings reported 
that with increasing age the level of recall decreases, while 
sex did not appear to influence recall of medication use.14,15 
In the PharmLines Initiative, we first conducted a cross-
sectional descriptive study to assess the concordance of the 
self-reported medication use that was documented at entry to 
the Netherlands Lifelines Cohort Study by comparing such 
information with the widely researched and representative Uni-
versity Groningen pharmacy prescription database IADB.nl. 
The IADB.nl was regarded as the “golden standard” for these 
analyses (see “Materials and methods” section for description). 
Further, we also aimed to describe the influence of the type of 
medication, age and sex on the concordance rates. 
Materials and methods
setting and study design 
In 2017, the Groningen Research Institute of Pharmacy, 
Department of Epidemiology and Clinical Pharmacy and 
Department of Pharmacology of the University Medical 
Center Groningen and the Lifelines Cohort Study (see 
https://www.lifelines.nl/researcher/about-lifelines) started 
the PharmLines Initiative to link data of the Lifelines Cohort 
Study to the University Groningen prescription database, 
IADB.nl. The Lifelines Cohort Study was started in the north 
of the Netherlands between 2006 and 2013 as an  academic 
resource for researchers worldwide. The study design 
concerns an observational follow-up study with long-term 
prospective measurements in a large population aiming to 
explore the interaction between genetic and environmental 
factors in the development of multifactorial diseases.16 In 
short, since all inhabitants in the Netherlands are registered 
with a general practitioner (GP), eligible participants were 
invited to participate in the Lifelines Cohort Study through 
their GP. A large number of GPs within the northern three 
provinces of the Netherlands (Friesland, Groningen and 
Drenthe) were involved and invited all their patients between 
the ages of 25 and 50 years, unless the participating GP con-
sidered the patient not eligible based on the following criteria: 
severe psychiatric or physical illness; limited life expectancy 
(<5 years); or insufficient knowledge of the Dutch language 
to complete a Dutch questionnaire. Subsequently, individuals 
who were interested to participate received detailed infor-
mation by mail about the Lifelines Cohort Study and an 
informed consent form. After the signed informed consent 
was received by the Lifelines organization, the participants 
received a baseline questionnaire and an invitation to a com-
prehensive health assessment at the Lifelines research site. 
More than 167,000 people from the three Northern provinces 
of the Netherlands participated in this three-generation study. 
During the entry period, participants completed a number of 
questionnaires, underwent a medical examination and bio-
logical samples including DNA were collected and stored. 
Methods that were employed to obtain information on the 
medication use were as follows: 1) by asking the participants 
about their medication use through a questionnaire and 2) by 
bringing their used medications at the time of the interview. 
All medications were then recorded by a doctor’s assistant. 
All prescribed medications were classified according to the 
Anatomical Therapeutic Chemical (ATC) coding scheme.17
In order to validate this self-reported Lifelines Cohort 
Study medication database in a cross-sectional study design, 
we compared it to the pharmacy prescription database of 
University of Groningen, IADB.nl, which we regarded as 
the “golden standard”. The IADB.nl database is a growing 
pharmacy database that in 2013 comprised more than 60 
public pharmacies and contained prescription data from 
approximately 600,000 patients in the northern part of the 
Netherlands. The coverage is approximately 20% of the 
inhabitants of the northern provinces. Except for a registra-
tion at the participating pharmacy, no specific inclusion 
or exclusion criteria were applied. In the Netherlands, all 
patients are registered at a pharmacy independent of their 
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Concordance study of medication usage in the lifelines Cohort study
found to be representative for the national population as a 
whole.18 Prescription data have been collected for almost 
20 years since 1994 and each patient is uniquely tracked in 
the system. The prescription records comprise information 
about the medication, for example, the date and quantity of 
dispensing, dosage of the administrated drug and the ATC 
code. The data are stored anonymously and all patients are 
given an anonymous patient code. Demographic information 
such as date of birth and sex is available. This database pro-
vides virtually complete medication records, except for OTC 
drugs and medication dispensed during hospitalization.18 
Pharmlines initiative: linkage and study 
population
In the PharmLines Initiative, both databases from the Life-
lines Cohort Study and IADB.nl were linked by Statistics 
Netherlands (CBS), which acted as Third Trusted Party at 
the patient level using deterministic linkage on the basis of 
unique identifiable information. The IADB.nl is a longitudi-
nal database that creates new patient records if information 
about a patient is changed. For instance, if a patient moves 
to another address, the new postal code together with all the 
patient information is stored in a new record. All these patient 
records were uploaded to the CBS for linkage. The linkage of 
IADB with the longitudinal database of the CBS was done 
in four steps. The first linkage was carried out on the full 6 
characters of the postal code in combination with sex and 
date of birth. In the second linkage, records of patients with 
the same IADB number as the already linked patients were 
added to the linked patients. The total linkage of these two 
steps gave a 48.3% linkage. The third linkage was done on 
the 4 digits of the postal code in combination with sex and 
date of birth. Again, only unique combinations of the CBS 
person number and the IADB.nl number were selected. In 
the fourth linkage, records of patients with the same IADB.nl 
number as the already linked patients were added to the 
linked patients. The total linkage of these two last steps gave 
a 42.8% linkage. Total linkage of all uploaded records was 
90.1%. Once the linkage was completed, all unique patient 
identifiers were removed by CBS. Each participant was then 
given an unique identifier code in order to be able to compare 
the medication use at a patient level for each included ATC 
code. The analysis was done in a password secured electronic 
environment provided by the CBS.
The study population was restricted to all adults (≥18 
years) for whom baseline information was recorded in the 
Lifelines Cohort Study database as well as in the IADB.nl 
database. The date on which the participants were enrolled 
in the IADB.nl database was at least 6 months before the 
Lifelines baseline measurement of each participant. Such 
restriction ensures that different time windows can be cho-
sen for the IADB.nl data, whilst the study population will 
remain unchanged. 
study parameters and data analysis
The linked information relevant to this study consisted of 
anonymized identifier codes, ATC codes, dispensing dates, 
date of entry in the IADB database, sex and age at the time 
of the first visit at entry to the cohort. The very first interview 
with the Lifelines Cohort Study participant was considered 
the baseline measurement and only the data of the baseline 
measurements (entry period) were used in the comparison 
of the two databases.
All drugs grouped at a second level of ATC coding were 
examined in the study. Besides the second level ATC codes, 
some specific drugs at the chemical level were included 
in the study. A top list of the several most commonly used 
drugs in the Netherlands including omeprazole, psylla 
seeds, macrogol, calcium, hydrochlorothiazide, metoprolol, 
enalapril, simvastatin, ketoconazole, triamcinolone, clo-
betasol, levothyroxine, oxazepam, temazepam, paroxetine, 
fluticasone, mometasone, salbutamol, salmeterol/fluticasone, 
desloratadine, artificial tears, carbasalate ca., diclofenac and 
ibuprofen was also examined. 
The program SQL Server was used to compare the records 
of drugs for each participant. The acquired data was then 
categorized in true positives, true negatives, false positives 
(FPs) and false negatives (FNs). These values were given in 
cross-tables, which were used to calculate the concordance. 
Each of the four cells in these cross-tables were required to 
have at least 5 participants. If the number of participants was 
lower than 5 in one or more cells, the drug group or specific 
drug was disregarded.
In order to address the possible underlying cause of a low 
agreement, the FNs and FPs were examined. Over-reporting 
represents the number of FPs. This means that a number of 
participants reported the use of a certain drug group, while 
at the same time the prescription was not registered in the 
pharmacy records. On the other hand, under-reporting repre-
sents the number of FNs. This means that the participants did 
not report the use of a certain drug group, while at the same 
time the prescription was registered in the pharmacy records. 
If a drug group or specific drug showed a poor agreement 
and at the same time a high over-reporting, it could indicate 
that the database with the self-reported data is better capable 
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The participants were also stratified on age and sex in order to 
investigate the influence of these factors on the concordance 
rates. This was only applied for a selection of most commonly 
used medications at lowest fifth level ATC codes (chemical 
substance specific coding). 
To determine if participants reported medication that they 
had not yet started to use in the period around the interview, 
but started to use earlier or immediately after the interview, 
we defined various overlapping time windows. The effect of 
the overlapping time window was examined and therefore 
a sensitivity analysis was performed for 6 different time 
windows. To determine the effect of different time windows 
on the outcome of the comparison of the databases, time 
windows of 30 days, 90 days, 105 days, 120 days and 180 
days before the baseline measurement were used. In addition 
to the previous time windows, a time window of 90 days 
prior and 2 weeks after the baseline measurement was chosen 
(referred to as 14–90 days). 
statistical methods
Medication data fields from both the Lifelines Cohort Study 
database and IADB.nl were blank if there was no medication 
recorded and present if there was an ATC code recorded. There-
fore, we could not establish missingness and assumed absence of 
medications if the record was blank. The Cohen’s kappa statistic 
was used to measure the concordance rate, and the pharmacy 
prescription data was considered as the golden standard. The 
95% CI for Cohen’s kappa was calculated using the standard 
error.19 The Cohen’s kappa values were interpreted according 
to the guidelines proposed by Altman et al: poor (<0.20), fair 
(0.20–0.40), moderate (0.41–0.60), good (0.61–0.80), very good 
(0.81–1.00).20 Since statistical comparisons of kappa measures 
have some limitations, we decided to interpret the 95% CIs of the 
Cohen’s kappa values. If these did not overlap for the respective 
comparison groups, the comparison was considered to indicate 
a significant difference. Statistical analyses were conducted with 
IBM SPSS software, version 25, 2017.
Results
After the linkage of the two databases, the total overlap con-
sisted of 45,000 adult Lifelines participants. For the current 
comparison applying the abovementioned strict eligibility 
criteria, 16,367 Lifelines participants who fulfilled the eligi-
bility criteria could be examined. Of the 16,367 persons, 64% 
were females and the mean age of the included population 
was 44 years. 
At the second level of ATC coding, the concordance 
between the two data sources varied from poor to very good 
for the various drug groups (see Table 1). The lowest concor-
dance was found between the two data sets for gynecologi-
cal anti-infectives (kappa [k]= 0.09; 95% CI: 0.04–0.15), 
whereas the best concordance was found for levothyroxine 
(H03AA01) (k= 0.84; 95% CI: 0.81–0.86, Table 2). Over-
all, drugs intended for chronic use showed a good to very 
good agreement between the two data sources including 
antidiabetic drugs, medication for the cardiovascular system, 
anti-thrombotic drugs, psychoanaleptics, medication for 
obstructive airway diseases, thyroid therapy, bisphosphonates 
and anti-gout agents. Surprisingly, some drug groups that may 
also be used chronically also showed a moderate concordance 
like for immunosuppressants, antineoplastics and cardiac 
therapeutics, though acute short-term use (<3 months) may 
be prevalent among the participants. 
Moderate agreement (k= 0.41–0.60) was mainly found for 
medications that were used most commonly for short-term 
use medication. This was found for anti-anemics, antihista-
mines, analgesics and nasal preparations. Medication used 
for short periods of time or topical application, for example, 
anti-acne drugs, antimycotics, antibacterials, triamcinolone, 
antifungals and antibiotics, showed a poor to fair agreement 
(k= 0–0.40). 
Remarkably, all included cardiovascular ATC groups 
showed an agreement of k= 0.61 or higher, except the cardiac 
therapy (C01) and vasoprotective (C05), which showed an 
agreement of k =0.60 and k= 0.21, respectively.
In Figure 1, the results of the different time windows 
used for the IADB database are shown. For each second 
level ATC code, the time window of 30 days resulted in a 
significant lower agreement between the two data sources. 
The other time windows did not show a significant difference. 
A detailed overview of the results according to the different 
time windows at all second level ATC codes can be found 
in Appendices 1–6.
In Figure, 2 the effect of age on the concordance between 
the two data sources is displayed. The concordance rates tend 
to increase with increasing age, but in most cases the 95% 
CIs show an overlap. The only significant difference in kappa 
values was found for the age groups 18–35 and 65+ years, and 
such differences could only be observed for levothyroxine, 
carbasalate calcium, diclofenac and omeprazole. Medication 
used topically showed no significant differences. Detailed 
results of the effect of the participants’ age on all concordance 
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Concordance study of medication usage in the lifelines Cohort study
Figure 3 displays results for a top list of most frequently 
used medication in the population. Kappa values of differ-
ent medication classes showed an overlap in concordance 
rates between males and females, which is indicative for no 
significant differences. Detailed results of the effect of the 
participants’ sex on the concordance rates of all studied types 
of medication can be found in Appendices 7 and 8.
Discussion
This concerns a descriptive study with the primary aim 
to describe concordance rates between self-reported and 
prescription medication data for an unselected population 
participating in the Lifelines Cohort Study, and to explore 
new relationships in the data. Overall, we have found that 
the concordance rates between the two data sources differ 
Table 1 Overview of all second level aTC codes including their respective kappa values and 95% Ci
ATC code Over-reporting (N) Under-reporting (N) Kappa (95% CI)
Drugs for acid-related disorders (a02) 642 312 0.64 (0.62–0.67)
Drugs for gastrointestinal disorders (a03) 67 51 0.50 (0.42–0.57)
Drugs for constipation (a06) 153 183 0.51 (0.47–0.56)
antidiarrheals (a07) 69 25 0.51 (0.42–0.59)
antidiabetics (a10) 97 14 0.83 (0.80–0.86)
antithrombotics (B01) 224 43 0.78 (0.75–0.80)
antianemics (B03) 176 57 0.52 (0.47–0.58)
Cardiac therapy (C01) 62 20 0.60 (0.52–0.68)
Diuretics (C03) 210 35 0.79 (0.77–0.82)
Vasoprotectives (C05) 23 82 0.21 (0.12–0.30)
Beta blocking agents (C07) 321 70 0.79 (0.76–0.81)
Ca2+ channel blockers (C08) 123 16 0.79 (0.75–0.82)
Drugs acting on the raas (C09) 346 35 0.81 (0.80–0.83)
lipid modifying agents (C10) 322 33 0.82 (0.80–0.84)
antifungals (D01) 99 187 0.26 (0.20–0.32)
Emollients (D02) 82 175 0.19 (0.13–0.25)
antipsoriatics (D05) 50 15 0.37 (0.25–0.49)
antibiotics (D06) 39 113 0.13 (0.06–0.20)
Corticosteroids (D07) 360 455 0.23 (0.19–0.26)
anti-acne drugs (D10) 16 36 0.39 (0.26–0.52)
gynecological anti-infectives (g01) 5 166 0.09 (0.04–0.15)
sex hormones (g03) 1343 413 0.43 (0.40–0.45)
Urologicals (g04) 49 47 0.70 (0.65–0.76)
Corticosteroids (h02) 49 157 0.28 (0.21–0.35)
Thyroid therapy (h03) 147 9 0.83 (0.81–0.86)
antibacterials (J01) 101 994 0.13 (0.11–0.16)
antimycotics (J02) 24 83 0.22 (0.12–0.31)
antivirals (J05) 21 19 0.43 (0.28–0.57)
antineoplastics (l01) 26 6 0.53 (0.38–0.67)
Endocrine therapy (l02) 23 7 0.72 (0.62–0.81)
immunosuppressants (l04) 77 11 0.54 (0.45–0.62)
Anti-inflammatory agents (M01) 516 624 0.33 (0.30–0.36)
anti-gout agents (M04) 17 5 0.67 (0.53–0.80)
Bisphosphonates (M05) 39 8 0.80 (0.75–0.86)
analgesics (n02) 527 181 0.43 (0.40–0.47)
antiepileptics (n03) 74 22 0.70 (0.65–0.76)
Psycholeptics (n05) 356 313 0.52 (0.49–0.55)
Psychoanaleptics (n06) 385 84 0.75 (0.73–0.77)
antiprotozoals (P01) 11 76 0.19 (0.09–0.28)
nasal preparations (r01) 466 280 0.51 (0.48–0.54)
Drugs for obstructive airway diseases (r03) 696 57 0.61 (0.59–0.64)
Cough and cold medications (r05) 31 155 0.17 (0.11–0.24)
antihistamines (r06) 542 155 0.50 (0.47–0.54)
Ophthalmologicals (s01) 177 318 0.40 (0.36–0.44)
Otologicals (s02) 22 128 0.13 (0.06–0.19)
Note: The number of people who over-reported or under-reported the medication usage is also displayed in order to gain insight into the cause of the respective high/
low kappa value. The displayed data are based on a time window of 90 days. The numbers in bold mean that the medications showed good and very good agreement (0.61 
and more).
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according to the therapeutic class and age. Medication used 
for example for the cardiovascular system and diabetes, 
thyroid therapy, anti-thrombotic drugs and medication for 
obstructive airway diseases showed a good to very good con-
cordance (k>0.60). This indicates that, at entry to the cohort, 
drugs intended for chronic use are reliably self-reported by 
patients, a finding which is in line with earlier studies.8–11
In contrast to our expectations, some chronically used 
medications, like antineoplastics and immunosuppressants, 
showed only a moderate kappa value. Since these medica-
tions are used for serious conditions and are typically used 
chronically, a high concordance between the two databases 
was expected.21 One possible explanation for the moderate 
kappa values is that antineoplastics and immunosuppressants 
are commonly started and dispensed in hospitals, and the use 
of such medication is possibly not accurately registered in 
the IADB.nl database. This is also supported by the fact that 
these medications are largely over-reported. Therefore, self-
reported data are required next to EMRs to more accurately 
obtain information on exposure rates to such medications.
Table 2 Overview of all included fifth level ATC codes including their respective kappa values and 95% CI
ATC code Over-reporting Under-reporting Kappa (95% CI)
Omeprazole (a02BC01) 453 267 0.63 (0.60–0.65)
Psylla seeds (a06aC01) 50 36 0.62 (0.54–0.69)
Macrogol (a06aD65) 83 106 0.43 (0.36–0.49)
Carbasalate ca. (B01aC08) 104 28 0.76 (0.72–0.80)
hydrochlorothiazide (C03aa03) 148 32 0.81 (0.78–0.84)
Metoprolol (C07aB02) 176 34 0.82 (0.80–0.84)
Enalapril (C09aa02) 75 13 0.79 (0.75–0.84)
simvastatin (C10aa01) 161 25 0.83 (0.80–0.85)
Ketoconazole (D01aC08) 51 92 0.25 (0.17–0.25)
Triamcinolone (D07aB09) 109 135 0.20 (0.14–0.26)
levothyroxine (h03aa01) 139 9 0.84 (0.81–0.86)
Diclofenac (M01aB05) 197 382 0.32 (0.28–0.36)
Oxazepam (n05Ba04) 112 109 0.43 (0.36–0.49)
Paroxetine (n06aB05) 91 14 0.79 (0.75–0.83)
Fluticasone (r01aD08) 166 107 0.51 (0.46–0.56)
salmeterol/Fluticasone (r03aC02) 157 24 0.65 (0.60–0.70)
Desloratadine (r06aX27) 221 91 0.51 (0.46–0.56)
Note: The number of people who over-reported or under-reported the medication usage is also displayed in order to gain insight into the cause of the respective high/
low kappa value. The displayed data are based on a time window of 90 days. The numbers in bold mean that the medications showed good and very good agreement (0.61 
and more).
Abbreviation: aTC, anatomical Therapeutic Chemical.
Figure 1 Kappa values for the different time windows (30 days, 90 days, 14–90 days, 105 days, 120 days and 180 days) with the corresponding 95% Ci for each second level 
aTC code.
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Concordance study of medication usage in the lifelines Cohort study
Medications intended for use on an as-needed basis over-
all showed a moderate (k=0.41–0.60) concordance, whereas 
medications used for short periods of time overall showed a 
poor to fair concordance (k=0–0.40). These medications are 
taken less often or on an irregular basis and therefore might 
be under-reported by the participants.7,13
Dermatologicals showed an overall poor to fair (k=0–
0.40) concordance. The reason for the low concordance can 
be attributed mostly to under-reporting of the medication use. 
This could be due to the reason that patients do not regard 
dermatologicals as medication and therefore under-reported 
the use of such medication.8
On the other hand, over-reporting was observed for drugs 
like sex hormones, analgesics, antihistamines and drugs for 
acid-related disorders. Such drugs are also OTC medica-
tions. Therefore, a large portion of their use is not recorded 
in the pharmacy database indicating that self-reported data 
may be a better way to capture the use of such medications. 
Figure 2 Kappa values and the corresponding 95% Ci are displayed for a selection of medications.
Notes: The participants are arranged in four age groups; 18–35, 36–45, 46–64 and 65+ years. For 9 classes of medication, data were less than 5 per cell to calculate kappa 








































































Figure 3 Kappa values stratified on sex. 
Note: The influence of sex on the agreement between data sources for a selection of medication is made clear. The error bars display the 95% CI. For 8 classes of medication, 
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Unexpectedly, most of the cardiovascular drugs were also 
over-reported to some extent. We can only speculate on the 
reasons and more research is needed to find the cause for 
this finding. 
It is remarkable that vasoprotectives and gynecological 
anti-infectives showed a poor concordance. These medical 
drugs are used for conditions like rectal fissures, hemorrhoids 
and genital infections. We may only speculate that patients 
do not like to disclose information about such conditions. 
Stigmatization bias could therefore be the reason for the 
low concordance between the two data sources. The fact that 
these medications are significantly under-reported supports 
this theory.
We studied the influence of time windows, sex and age 
on the concordance rates. Methodologically, time windows 
are important in concordance studies to draw valid conclu-
sions. In the Netherlands, chronically used medications are 
prescribed every 3 months. Therefore, the time window of 
30 days resulted in a significantly lower concordance for 
chronically used medication. However, for medication used 
for short periods of time such as antifungals and antimycotics, 
the results for the time window of 30 days did not significantly 
differ from the other time windows. In fact, the 30-day time 
window resulted in a higher concordance for medications 
like antibacterials and antiprotozoals. The remaining time 
windows did not differ significantly from each other. The 
current use of a medication is determined by the amount of 
medication that is prescribed at a certain time point. A time 
window that is too large is not suitable to represent the current 
medication use of a participant and most studies done so far 
used a time window of 90 days. Therefore, it is advisable to 
use the time window of 90 days for future research. In line 
with earlier studies, no effect of sex on the concordance was 
found. However, in contrast to earlier findings, an increase 
in age seems to result in an increase in agreement.14,15 Even 
though an increase in age seems to go hand in hand with an 
increase in concordance, the 95% CIs overlap in most cases. 
The included study population consists of a relative young 
population with a mean age of 44 years and this could be 
the reason of the difference in the effect of age on the recall 
of medication. Older people generally use more medication 
and have lower cognitive abilities than younger people, and 
thus the concordance between the two databases could be 
significantly lower for an older population. A larger popula-
tion size may lead to smaller CIs and may help create a better 
understanding of the influence that the participants’ age has 
on the medication recall. 
There are some limitations to our study. Though this was 
one of the largest studies to date on the concordance of self-
reported data on medication use, the number of participants 
using certain medication classes was still low. Some ATC codes 
could not be included as there were not enough data. As the size 
of the IADB.nl database will increase over time, the overlap 
of the two databases will also grow. This makes it possible to 
include more participants in future studies. Further, we could 
not establish missingness and assumed absence of medications 
if the record was blank. If anything, this would lead to potential 
random misclassification. Finally, in a previous study it was 
shown that the adult Lifelines cohort population is representa-
tive of the Dutch adult population. However, medication use is 
very culture-dependent and the results may not be applicable 
directly to countries with other health care systems.22 
To conclude, the concordance between the self-report 
database and the prescription database varied per therapeutic 
group. The self-reported method as applied by the Lifelines 
Cohort Study is valid for capturing most medications that 
are intended for chronic use and OTC medications. How-
ever, it is less suitable for recording medications used on an 
as-needed basis, medications used for short periods of time 
and/or topical medications. Stigmatization bias could have a 
large influence on the self-report of certain medication classes 
like vasoprotectives and gynecological anti-infectives. Sex 
does not influence the concordance, and an increase in age 
tended to result in a slightly better recall. However, more 
studies on the effects of age on the concordance are needed. 
Future pharmaco-epidemiological studies should preferably 
combine the two data sources to achieve the highest accuracy 
of drug exposure rates. 
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